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Abstract
Engagement of toll-like receptors (TLRs) serve to link innate immune responses with adaptive immunity and can be
exploited as powerful vaccine adjuvants for eliciting both primary and anamnestic immune responses. TLR7 agonists are
highly immunostimulatory without inducing dominant proinflammatory cytokine responses. We synthesized a dendrimeric
molecule bearing six units of a potent TLR7/TLR8 dual-agonistic imidazoquinoline to explore if multimerization of TLR7/8
would result in altered activity profiles. A complete loss of TLR8-stimulatory activity with selective retention of the TLR7-
agonistic activity was observed in the dendrimer. This was reflected by a complete absence of TLR8-driven proinflammatory
cytokine and interferon (IFN)-c induction in human PBMCs, with preservation of TLR7-driven IFN-a induction. The dendrimer
was found to be superior to the imidazoquinoline monomer in inducing high titers of high-affinity antibodies to bovine a-
lactalbumin. Additionally, epitope mapping experiments showed that the dendrimer induced immunoreactivity to more
contiguous peptide epitopes along the amino acid sequence of the model antigen.
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Introduction
Toll-like receptors (TLRs) are pattern recognition receptors that
recognize specific molecular patterns present in molecules that are
broadly shared by pathogens, but are structurally distinct from
host molecules [1,2]. The activation of TLRs by their cognate
ligands leads to activation of innate immune effector mechanisms,
including the production of pro-inflammatory cytokines, and up-
regulation of major histocompatibility complex (MHC) molecules
and co-stimulatory signals in antigen-presenting cells. The
activation of the innate immune system serves to mobilize and
amplify subsequent specific adaptive immune responses involving
both T- and B-cell effector functions [3–6]. Thus, TLR stimuli
serve to link innate and adaptive immunity [4] and can therefore
be exploited as powerful adjuvants in eliciting both primary and
anamnestic immune responses.
At least 10 TLRs are encoded in the human genome [2]. The
ligands for these receptors are highly conserved microbial
molecules such as lipopolysaccharides (LPS) (recognized by
TLR4), lipopeptides (TLR2 in combination with TLR1 or
TLR6), flagellin (TLR5), single stranded RNA (TLR7 and
TLR8), double stranded RNA (TLR3), CpG motif-containing
DNA (recognized by TLR9), and profilin present on uropatho-
genic bacteria (TLR 11) [7]. TLR1, -2, -4, -5, and -6 respond to
extracellular stimuli, while TLR3, -7, -8 and -9 respond to
intracytoplasmic pathogen-associated molecular patterns
(PAMPs), being associated with the endolysosomal compartment
[2].
In evaluating representative members of virtually all known
TLR agonists in a series of hierarchical assays including primary
TLR-reporter assays, secondary indices of immune activation such
as cytokine induction and activation of lymphocytic subsets in
whole human blood, and tertiary screens characterizing tran-
scriptomal activation patterns with a view to identifying optimal
immunostimulatory chemotypes [8], we found that TLR7
agonists, represented by the imidazoquinoline chemotype (Com-
pound 2, Fig. 1), were extraordinarily immunostimulatory.
Extensive structure-activity relationship studies [9–13] led to the
synthesis of a highly potent TLR7/TLR8 dual-agonistic 1-(4-
(aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine
(Compound 4, Fig. 2), whose free primary amine on the N1-benzyl
substituent proved a convenient and versatile handle for the
attachment of fluorophores [11] as well as a precursor for model
self-adjuvanting subunit vaccine constructs with the imidazoquino-
line covalently attached to the antigen [13].
Initiation of signaling by TLRs involve homotypic or hetero-
typic dimerization [14,15], and we have previously explored the
activities of dimeric imidazoquinoline constructs [12]. We asked if
a multimeric (dendrimeric) construct of 4 would alter its activity
profile. We therefore synthesized a dendrimeric molecule bearing
six units of the TLR7/TLR8 dual-agonistic imidazoquinoline 4.
Upon dendrimerization, however, we noted a complete loss of
TLR8-stimulatory activity, with selective retention of the TLR7-
agonistic activity of its parent monomer in primary screens
employing TLR-specific reporter gene assays. This was reflected
by a complete absence of TLR8-driven proinflammatory cytokine
and interferon (IFN)-c induction in human PBMCs, but with
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preservation of TLR7-driven IFN-a induction. The dendrimer
was found to be superior to the imidazoquinoline monomer in
inducing high titers of high-affinity antibodies. Additionally,
epitope mapping experiments showed that the dendrimer induced
immunoreactivity to more contiguous peptide epitopes along the
amino acid sequence of bovine a-lactalbumin.
Materials and Methods
All of the solvents and reagents used were obtained commer-
cially and used as such unless noted otherwise. Moisture- or air-
sensitive reactions were conducted under nitrogen atmosphere in
oven-dried glass apparatus. The solvents were removed under
reduced pressure using standard rotary evaporators. Flash column
chromatography was carried out using RediSep Rf ‘Gold’ high
performance silica columns on CombiFlash Rf instrument unless
otherwise mentioned, while thin-layer chromatography was
carried out on silica gel CCM pre-coated aluminum sheets. All
intermediates and final target compounds were characterized by
1H and 13C NMR; spectra were verified to be consistent with their
structure. Purity for all final compounds was confirmed to be
greater than 97% by LC-MS using a Zorbax Eclipse Plus 4.6 mm
6150 mm, 5 mm analytical reverse phase C18 column with H2O-
isopropanol or H2O-CH3CN gradients and an Agilent ESI-TOF
mass spectrometer (mass accuracy of 10 ppm) operating in the
positive ion acquisition mode.
Synthesis of Compound 3: 1,1’,1’’-(nitrilotris(ethane-2,1-
diyl))tris(3-(4-((4-amino-2-butyl-1H-imidazo[4,5-
c]quinolin-1-yl)methyl)benzyl)thiourea)
To a solution of compound 1 (4.2 mg, 0.29 mmol) in pyridine
(1 mL) was added compound 2 (46 mg, 1.16 mmol). The reaction
mixture was heated at 45uC for 2 h, followed by the addition of
polystyrene bound-NH2 beads (PS-NH2, Biotage) to quench the
excess of compound 2. The reaction was stirred for another
30 min, followed by filtration to remove the beads. The filtrate was
concentrated under vacuum and the residue was washed several
times with diethyl ether to afford compound 3 (22 mg, 56%). MS
(ESI) calculated for C75H87N19S3, m/z 1349.65, found 1350.66
(M + H)+ and 675.83 (M +2H)+2.
Synthesis of Compound 6: N-(4-((4-amino-2-butyl-1H-
imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)-2-
azidoacetamide
To a solution of 1-bromo acetic acid (52 mg, 0.37 mmol) in
anhydrous N,N-dimethylformamide (DMF) were added, triethyla-
mine (130 mL, 0.93 mmol), 50 wt% propylphosphonic anhydride
(T3PH) solution in ethylacetate (0.3 mL, 0.48 mmol) and com-
pound 4 (160 mg, 0.37 mmol). The reaction mixture was stirred
for 2 h followed by removal of the solvent under vacuum. The
residue was then dissolved in ethylacetate and washed thrice with
water and brine. The ethylacetate fraction was dried over
anhydrous sodium sulfate and then concentrated under vacuum
to obtain the crude compound 5 (95 mg). To the solution of
compound 5 (95 mg, 0.2 mmol) in anhydrous DMF were added,
triethylamine (33 mL, 0.24 mmol) and sodium azide (26 mg,
0.4 mmol). The reaction mixture was then heated at 60uC for
30 min, followed by removal of the solvent under vacuum to
obtain the residue which was purified using column chromatog-
raphy to obtain the compound 6 (55 mg, 34%). 1H NMR
(500 MHz, MeOD) d 7.82 (d, J = 8.3 Hz, 1H), 7.66 (d, J
= 8.4 Hz, 1H), 7.43 (dd, J = 11.3, 4.1 Hz, 1H), 7.28 (d, J
= 8.1 Hz, 2H), 7.12 (t, J = 7.7 Hz, 1H), 7.03 (d, J = 8.1 Hz, 2H),
5.87 (s, 2H), 4.37 (s, 2H), 3.89 (s, 2H), 3.00–2.92 (m, 2H), 1.79 (dt,
J = 15.4, 7.6 Hz, 2H), 1.44 (dd, J = 15.0, 7.5 Hz, 2H), 0.93 (t, J
= 7.4 Hz, 3H). 13C NMR (126 MHz, MeOD) d 170.15, 156.38,
152.54, 144.50, 139.57, 136.25, 135.70, 129.50, 128.68, 126.92,
125.92, 123.60, 121.68, 115.71, 52.96, 49.62, 43.62, 30.88, 27.84,
23.43, 14.09. MS (ESI) calculated for C24H26N8O, m/z 442.2230,
found 443.2345 (M + H)+.
Figure 1. Synthesis of trimeric imidazoquinoline dendrimer 3.
doi:10.1371/journal.pone.0043612.g001
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Synthesis of Compound 7: N1,N1-bis(2-(di(prop-2-yn-1-
yl)amino)ethyl)-N2,N2-di(prop-2-yn-1-yl)ethane-1,2-
diamine
To a solution of compound 1 (299 mL, 2.0 mmol) in CH3CN
(20 mL) was added triethylamine (1.75 mL, 12.6 mmol). The
reaction mixture was cooled to 0uC and propargyl bromide (80%
solution in toluene, 2 mL, 13.5 mmol) was added drop wise over
a period of 10 min and the reaction mixture was kept stirring at
room temperature for 6 h. Water was added to the reaction
mixture and the product was extracted in ethyl acetate. The
Figure 2. Synthesis of Click reaction derived imidazoquinoline dendrimer 8.
doi:10.1371/journal.pone.0043612.g002
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Figure 3. TLR7- and TLR8-agonism and IFN-a and IFN-c induction by Compounds 3, 4, and 8. Top: TLR7- and TLR8-agonistic activity.
Reporter gene assays specific for human TLR7 and TLR8 were used. Data points represent means and SD of quadruplicates. Bottom: IFN-a and IFN-c
induction by Compounds 4 and 8 in human PBMCs, assayed by analyte-specific ELISAs. Data points represent means of duplicates of three
representative experiments.
doi:10.1371/journal.pone.0043612.g003
A Potent Adjuvantic Imidazoquinoline Dendrimer
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organic layer was washed with water (2620 mL), brine (2620 mL)
and dried over anhydrous sodium sulfate and concentrated under
vacuum. The crude residue was column purified to afford
compound 7 as thick liquid (433 mg, 58%). 1H NMR
Figure 4. Cytokine induction by Compounds 4 and 8 in human PBMCs. Data points of dose-response profiles represent means of duplicates
of three representative experiments. Cytokines were quantified using cytometric bead array assays.
doi:10.1371/journal.pone.0043612.g004
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(500 MHz, CDCl3) d 3.47 (d, J = 2.4 Hz, 12H), 2.66 (s, 12H),
2.23 (t, J = 2.4 Hz, 6H). 13C NMR (126 MHz, CDCl3) d 78.99,
73.23, 52.76, 50.65, 42.71. MS (ESI) calculated for C24H30N4, m/
z 374.25, found 375.25 (M + H)+.
Synthesis of Compound 8
To a stirred solution of compound 7 (5.0 mg, 0.013 mmol) and
6 (40 mg, 0.091 mmol) in DMF (2 mL), were added Cu-
SO4.5H2O (23 mg in 0.5 mL water, 0.091 mmol) and sodium
ascorbate (36 mg in 0.5 mL water, 0.18 mmol) and the reaction
mixture was stirred at room temperature for 1 h. The dendrimer
formed was purified by semi-preparative reverse phase HPLC to
afford compound 8 as solid (15 mg, 38%). MS (ESI) calculated for
C168H186N52O6, m/z 3027.5848, found 1514.8233 (M +2H)+2
and 1010.8771 (M +3H)3+.
TLR7 and TLR8-specific Reporter Gene Assays
The induction of nuclear factor-kappa B (NF-kB) was quantified
using Human Embryonic Kidney (HEK)-Blue-7 cells and HEK-
Blue-8 cells stably expressing human TLR7 and human TLR8,
respectively, as previously described by us [8,9].
Assays for IFN-a, IFN-c, and Cytokines
Fresh human peripheral blood mononuclear cells (PBMCs)
were isolated from human blood obtained by venipuncture using
conventional Ficoll-Hypaque gradients as described elsewhere
[12]. Venipuncture was performed with informed, written consent
on healthy adult males with no acute illnesses. Venipuncture
procedures were approved by the University of Kansas Human
Subjects Committee (KU-HSCL Approval # 12397). Aliquots of
PBMCs (105 cells in 100 mL/well) were stimulated for 12 h with
graded concentrations of test compounds. Supernatants were
isolated by centrifugation, diluted 1:20, and were assayed in
triplicates using a high sensitivity analyte-specific enzyme-linked
immunosorbent assays (ELISA) kits (PBL Interferon Source,
Piscataway, NJ and R&D Systems, Inc., Minneapolis, MN).
Cytokine production was examined using a FACSArray multi-
plexed flow-cytometric bead array (CBA) system (Becton-Dick-
inson-Pharmingen, San Jose, CA) as described by us previously
[16].
Rabbit Immunization
All experiments were performed at Harlan Laboratories
(Indianapolis, IN) in accordance with institutional guidelines
(University of Kansas IACUC permit # 119-06) which specifically
approved this study. All antigen/adjuvant preparations were
entirely aqueous; no liposomal or emulsifying agents were used.
Cohorts of adult female New Zealand White rabbits (n = 3) were
immunized intramuscularly in the flank region with (a) 100 mg of
bovine a-lactalbumin in 0.2 mL saline, or (b) 100 mg of bovine a-
lactalbumin plus 100 mg of 4 in 0.2 mL saline, or (c) 100 mg of
bovine a-lactalbumin plus 100 mg of 8 in 0.2 mL saline, or (d)
100 mg of bovine a-lactalbumin plus 100 mg of a high-potency,
pure TLR7-agonistic imidazoquinoline (1-benzyl-2-butyl-1H-imi-
dazo[4,5-c]quinolin-4-amine; reported as Compound 31 in Ref.
9). Pre-immune test-bleeds were first obtained via venipuncture of
the marginal vein of the ear. Animals were immunized on Days 1,
15 and 28. A final test-bleed was performed via the marginal vein
of the ear on Day 38. Sera were stored at 280uC until used.
Enzyme-linked Immunosorbent Assays (ELISA)
Bovine a-lactalbumin-specific ELISAs were performed in 384-
well format using automated liquid handling methods as described
by us [13]. Examination of the affinity of antigen-specific IgG
using chaotropic ELISA [17,18]. A precision 2000 liquid handler
(Bio-Tek, Winooski, VT) was used for all serial dilution and
reagent addition steps, and a Bio-Tek ELx405 384-well plate
washer was employed for plate washes; 100 mM phosphate-
buffered saline (PBS) pH 7.4, containing 0.1% Tween-20 was used
as wash buffer. Nunc-Immuno MaxiSorp (384-well) plates were
coated with 30 mL of a-lactalbumin in 100 mM carbonate buffer,
pH 9.0 overnight at 4uC. After 3 washes, the plates were blocked
with 3% bovine serum albumin (in PBS, pH 7.4) for 1 h at rt.
Serum samples (in quadruplicate) were serially diluted in a separate
384-well plate using the liquid handler. After three additional
washes of the assay plate, 30 mL of the serum dilutions were
transferred using the liquid handler, and the plate incubated at
37uC for 2 h in the absence or presence of graded (2M and 4M)
concentrations of sodium thiocyanate. The assay plate was washed
three times, and 30 ml of 1:10,000 diluted appropriate anti-mouse
immunoglobulin (IgG [c chain], IgM [m chain], IgG1, IgG2a)
conjugated with horseradish peroxidase was added to all wells.
Following an incubation step at 37uC for 1 h, and three washes,
tetramethylbenzidine substrate was added at concentrations
recommended by vendor (Sigma). The chromogenic reaction
was terminated at 30 min by the addition of 2M H2SO4. Plates
were then read at 450 nm using a SpectraMax M4 device
(Molecular Devices, Sunnyvale, CA).
Linear Epitope Mapping (ELISA)
Linear peptide epitope mapping were performed utilizing
PEPperMAPH technology (PEPperPRINT GmbH, Heidelberg,
Germany). Immune sera (Day 38) from three animals in each
cohort were used. The C- and N-termini of the bovine a-
lactalbumin were first elongated by neutral GSGSGSG sequences
to avoid truncated peptides. The protein sequence was then
translated into 13-mer peptides with a peptide-peptide overlap of
12 amino acids. Arrays of 129 peptides were printed in duplicate
spots; four such arrays were printed on each glass slide. Each array
was framed by a fusion tag (Flag) peptide (DYKDDDDKGG, 72
spots) and influenza virus hemagglutinin (HA) epitope tag peptide
(YPYDVPDYAG, 72 spots) as controls. After pre-swelling the
arrays for 10 min in standard buffer (phosphate-buffered saline
[PBS], pH 7.4+0.05% Tween 20) and 60 min in Rockland
blocking buffer (Rockland Immunochemicals, Inc., Gilbertsville,
PA), the peptide microarrays were initially incubated with the
secondary goat anti-rabbit IgG (H+L) conjugated with Dy-
Light680 antibody at a dilution of 1:5000 for 60 min at room
temperature to verify that no significant background interactions
occurred with the peptide arrays. The microarrays were washed
twice, and incubated for an additional 30 min in standard buffer.
The peptide arrays were then incubated overnight at 4uC with
rabbit sera diluted to 1:1000. After multiple washes in standard
buffer, the slides were incubated for 30 min with the secondary
goat anti-rabbit IgG (H+L) conjugated with DyLight680 antibody
at a dilution of 1:5000 at room temperature. After two additional
washes in standard buffer, the microarrays were rinsed with
ultrapure water and dried in a stream of air. Green/red
fluorescence intensities were acquired on an Odyssey Imager
(Lincoln, NE) at a spatial resolution of 21 mm. Staining of Flag and
HA control peptides that frame the arrays gave rise to high and
homogeneous spot intensities with a coefficient of variation of
,2%. The PEPSlide Analyzer algorithm deconvolutes raw
fluorescence intensities of each spot into foreground and
background signal. Intensity maps were generated based on
corrected foreground intensities (averaged over the double spots) of
each peptide.
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Figure 5. Anti-bovine a-lactalbumin-specific IgG titers. Top: Anti-bovine a-lactalbumin-specific IgG titers in rabbits adjuvanted with 4, 8,
a TLR7-specific imidazoquinoline (1-benzyl-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine; reported as Compound 31 in Ref. 9), and unadjuvanted
controls (n = 3 per cohort). Ratios of immune/pre-immune titers yielding absorbance values of 1.0 are shown for the individual samples. Each symbol
corresponds to the titer of a single animal. Bottom: Chaotropic ELISA showing apparent titers as a function of chaotrope (NaSCN) concentration.
Means and SD are shown.
doi:10.1371/journal.pone.0043612.g005
A Potent Adjuvantic Imidazoquinoline Dendrimer
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Results and Discussion
As mentioned earlier, we were desirous in examining dendri-
meric constructs of the imidazoquinoline with to view to testing
the hypothesis that such larger constructs may enhance adjuvan-
ticity. We did not, however, know a priori if such molecules would
even retain TLR7/8 agonistic activity. Our first attempt at
evaluating such dendrimeric molecules began with the synthesis of
3 (Fig. 1) which was accomplished by reacting an isothiocyanate
derivative 2 that we had used earlier [11,13] with the triamine 1.
We were gratified that this trimeric molecule 3 retained, in large
measure, both the TLR7- and TLR8-agonistic activities of the
parent monomeric imidazoquinoline (Fig. 1). We next extended
our efforts in synthesizing a hexameric construct 8, which was
obtained via a ‘click’ reaction of the azide-bearing 6 with the hexa-
alkyne 7 (Fig. 2). To our surprise, we noted that while the
dendrimer 8 retained substantial TLR7-agonistic activity, its
TLR8-stimulating properties appeared entirely abrogated in
primary screens employing reporter gene assays (Fig. 3).
In recognition that bioactivity readouts using cell-culture
systems may not always reflect with fidelity in vivo behavior
owing to a variety of reasons, including differential plasma protein
binding (that we ourselves have observed and characterized) [19],
it was important to verify that the activity profiles observed in
TLR-specific reporter gene assays was also seen in primary human
cells. It is to be noted that we [10,16,20] and others [21–23] have
shown that pure TLR7 agonists selectively induce Type I
interferons, while the production of IFN-c and proinflammatory
cytokines is attributable primarily to TLR8 activation. We
confirmed that the dendrimer was selectively bereft of TLR8-
agonistic properties in secondary screens using human PBMCs in
which the dendrimer 8, unlike its parent monomer 4, showed
Figure 6. Linear peptide epitope mapping results of immune sera. Top: Foreground fluoresence intensities of secondary goat anti-rabbit IgG
(H+L) conjugated with DyLight680 antibody to each overlapping 13-mer peptide in the microarray are shown (means and SD). Bottom: Raw
fluorescence images of representative peptide microarrays are shown. Each array is framed by a fusion tag (Flag) peptide (DYKDDDDKGG, 72 red
spots) and influenza virus hemagglutinin (HA) epitope tag peptide (YPYDVPDYAG, 72 green spots) which were used as internal controls.
doi:10.1371/journal.pone.0043612.g006
A Potent Adjuvantic Imidazoquinoline Dendrimer
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Figure 7. Mapping of immunoreactive linear epitopes of bovine a-lactalbumin to its primary sequence and crystal structure. Top:
Sequence homology between bovine and rabbit a-lactalbumin. Conservative and non-conservative changes are shown in blue and red, respectively.
Bottom: Mapping of immunoreactive linear epitopes to the crystal structure of bovine a-lactalbumin (PDB code: 1F6R). Regions colored green show
contiguous immunodominant epitopes elicited by both 4 and 8, while regions colored red show additional epitopes specifically adjuvanted by 8.
doi:10.1371/journal.pone.0043612.g007
A Potent Adjuvantic Imidazoquinoline Dendrimer
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selective induction of TLR7-driven IFN-a, but not of IFN-c
(Fig. 3), or proinflammatory cytokines such as TNF-a, IL-1b, and
IL-6 (Fig. 4).
It is to be noted that both in interferon (Fig. 3) and in cytokine-
release assays (Fig. 4), a bimodal dose-response profile character-
ized by an initial dose-dependent increase in analyte concentration
followed by an apparent suppression in interferon/cytokine
production was observed as we have previously reported
[10,13,16]. The origin and cause of this bimodal response is not
clear, but we verified that this is not due to cytotoxicity using
standard XTT [24] and resazurin [25] assays.
Immunization of rabbits with bovine a-lactalbumin with either
the monomeric compound 4 or the dendrimer 8 elicited strong
humoral responses (Fig. 5); however, although not statistically
significant owing to the small sample sizes, anti-a-lactalbumin IgG
titers in rabbits adjuvanted with 8 were higher than titers elicited
by 4, or a high-potency, pure TLR7-agonistic imidazoquinoline
(1-benzyl-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine; reported as
Compound 31 in Ref. 9) (Fig. 5). Affinity measures of antibody
quality using chaotropic ELISAs also indicated that the use of 8 as
adjuvant resulted in significantly higher-affinity antibodies (Fig. 5).
Linear epitope mapping clearly showed that the dendrimer 8
induced immunoreactivity to more contiguous peptide epitopes
along the amino acid sequence of bovine a-lactalbumin. First,
a pronounced immunoreactivity to a peptide sequence centered
around amino acids 42–54 (VQNNDSTEYGLFQ) was observed
in animals adjuvanted with 8; second, higher immunoreactivity to
peptide sequences centered on amino acids 6–18 (CEV-
FRELKDLKGY) and 108–120 (KALCSEKLDQWLC) were also
observed (Fig. 6). These data clearly show that immunization with
8 as adjuvant extends the immunoreactivity profile of the humoral
response to encompass longer stretches of the amino acid sequence
of the protein antigen. These results were somewhat unexpected
because an examination of the amino acid sequences of bovine
and rabbit a-lactalbumin shows differences throughput the length
of the protein (Fig. 7; Waterman-Eggert score: 579; 61.2%
identity; 85.1% similar), and we had surmised, perhaps naı̈vely,
that the immunoreactivity patterns of linear epitopes in the
monomer- and dendrimer-adjuvanted samples would be very
similar, with the dendrimer evoking stronger responses. The
mechanism(s) underlying the superior adjuvanticity of 8 are
unknown; we hypothesize that this may be related to the lack of
induction of counter-regulatory IL-10.
The availability of experimentally determined linear epitope
mapping data provided an opportunity to test and benchmark
known linear epitope prediction algorithms [26]. We compared six
methods that are implemented in Immune Epitope Database
Analysis Resource (www.immuneepitope.org): (a) Chou-Fasman b-
turn prediction propensity [27]; (b) Emini surface accessibility
parameter [28]; (c) Karplus and Schulz flexibility prediction [29];
(d) Kolaskar and Tongaonkar method [30]; (e) Parker hydrophi-
licity prediction [31]; (f) Bepipred linear epitope prediction method
[32]. The Parker hydrophilicity predicition algorithm yielded
a profile that correlated best with the experimentally-determined
linear epitope immunoreactivity patterns (Fig. 8).
It would also be pertinent to note two additional points: First,
the absolute concentration of 100 mg/dose of 4 and 8 are,
respectively, 278 nMoles and 33 nMoles; therefore, lower
concentrations of 8 exhibits higher adjuvantic activity than 4,
inducing higher titers of antibodies, which are also of higher
quality as adjudged by chaotropic ELISA and epitope mapping.
Second, although no apparent local or systemic adverse effects
were reported for any of the rabbits, the dendrimer 8, unlike 4, is
a pure TLR7 agonist, inducing only Type I IFN, and no
proinflammatory cytokines. Based on current paradigms, one
would predict far lower reactogenicity for 8. Accordingly,
a detailed comparison of local and systemic reactogenicity with
biomarker profiling is being planned.
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Figure 8. Correlation of observed and predicted epitopes.
Overlay of normalized mean background-corrected fluorescence in-
tensity (13-mer peptide-specific immunoreactivity) of the dendrimer 8-
adjuvanted rabbit sera and normalized Parker Hydrophilicity parameter
computed with a moving window of 13 residues.
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